SMMT - CIK 0001599298
Summit Therapeutics Inc. trades as SMMT and has a market capitalization of $10.13 B, making it the #935 largest US-listed company by market value. In its fiscal 2024 annual report the company posted revenue of $0.00 and net income of -$1.08B. This page tracks Summit Therapeutics Inc. through 532 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin compressed from -163.6% to -11174.8% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-04-30 |
| Major company event | 8-K | 2026-04-30 |
| Proxy materials | DEFA14A | 2026-04-17 |
| Annual report to shareholders | ARS | 2026-04-17 |
| Proxy statement | DEF 14A | 2026-04-17 |
| PRE 14A | - | 2026-04-06 |
| Annual report | 10-K | 2026-02-23 |
| Major company event | 8-K | 2026-02-23 |
_Overall Survival Data to be Featured at ASCO 2026 Plenary Session as Late-Breaking Abstract from HARMONi-6, a Phase III Study in 1L Squamous NSCLC in China_
_Three Poster Presentations Will Feature Updated Ivonescimab Data, including Intracranial Anti-Tumor Activity from the Global HARMONi Phase III Study_
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in three upcoming investor conferences during March of this year. Members of the Summit leadership team will participate in individual investor meetings along with some fireside chats at the following conferences:
The largest companies sharing Summit Therapeutics Inc.'s SEC industry classification (pharmaceutical preparations).
Summit Therapeutics Inc. (SMMT) has a market capitalization of $10.13 B as of 2026-06-10, ranking #935 among US-listed companies.
Summit Therapeutics Inc. reported revenue of $0.00 for fiscal year 2024.
In its latest fiscal year Summit Therapeutics Inc. reported a net loss of $1.08B.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.